Bought the seat, waiting for the ride: management describes a position already secured inside someone else's decision, w
The model's full reasoning — Q4 2017 call → NOWe need to determine if the transcript conveys that the company's near-term growth no longer depends on persuading anyone because decisions have already been made by others, and the company is preparing to deliver, and the company is small relative to the committed business. Let's analyze the transcript. Key points from management: - Dave Stack discusses the opioid epidemic and EXPAREL's position. He mentions partnerships with J&J, Cancer Treatment Centers, etc. He talks about strategic pillars: clinical data, education, partnerships. - On guidance: Charlie Reinhart says 2018 sales guidance $300-310 million, which aligns with 2017 growth rates. He says "While we are very confident in the growth initiatives that are now in place, especially the investment of our partner J&J is making in EXPAREL, projecting the timing of when each of these items will translate into accelerated growth is difficult to predict with certainty." This suggests growth is expected but timing uncertain. - Dave Stack on guidance: "we have not done a good job over the last couple of years of making sure that we've met the guidance that we put out there, so we wanted to be appropriately conservative... we've got a number of moving parts, the CMS initiatives, the commercial payer initiatives, the resolution of the nerve block AdCom... all of those things make it difficult for us to project exactly the timing of when these increases are going to take place." So they are conservative. - On CMS reimbursement: Dave says "We are engaged in very constructive discussions with CMS. We still believe that there is a possibility that we will get an off-cycle J code during 2018. And at the same time we are working through the normal CMS cycle... it is a very material opportunity." This is still a possibility, not a done deal. They are working to achieve it. - On J&J partnership: Scott Braunstein says "Our collaboration with J&J continues to advance... In just one year, we have created an energy and enthusiasm that is palpable and from which we expect to produce great results. We're thrilled with the resources J&J is investing in EXPAREL and their shared commitment in providing an opioid alternative to as many patients as possible." They talk about account activation, PEAK programs, educational programs, etc.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GOGO · Q1 2016 → YESThe question is whether management conveys that the company's near-term growth no longer depends on persuading anyone, because decisions have already been made by others, and activity has just begun t...YES The transcript shows management describing 2Ku awards exceeding 1000 aircraft as already decided by airlines (IAG, Air Canada, Delta, Shareco), with activity now centered on installation, STCs, and supply chain mobilization rather than further persuasion.
GIII · Q4 2024 → YESThe question is whether management conveys that the company's near-term growth no longer depends on persuading anyone, because decisions have already been made by others, and activity has just begun t...
FLL · Q3 2022 → YESThe question is about whether management conveys that the company's near-term growth no longer depends on persuading anyone, because decisions have already been made by others, and activity has just b...